Managing Director
Joined: 2004
and access,
Dean Slagel has 30 years of biopharmaceutical industry and venture investing experience and an MBA from ENPC Business School, Paris. Following 10 years with Ferring in global operations and business development management, he led Esperante since 2004, building an investment portfolio across North America, Europe and Israel with 3 successful exits and 2 successful public listings.
